focus -WSS

focus

author：focus 2025-09-29 22:37:06 - browse：62126

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： How Brent Saunders' Allergan experiment failed

WSS

Trump Organization, Michael Cohen agree to settle million

Elizabeth Holmes banned from government health programs

Humana cuts profit projections as Medicare Advantage costs soar

Biden White House, tech companies launch new safeguards around emerging AI technology

The tragedy of Johnson & Johnson’s Covid vaccine

Why Marc Tessier

knowledge

focus

focus

Peter Hotez and the public health issue of online harassment

Study: Misdiagnosis causes 800,000 deaths, serious disabilities a year in U.S.

In Memoriam: Notable people who died in 2023

Pfizer's RSV vaccine recommended for approval in Europe

Walensky prepares to leave CDC — and Congress — behind

Why the advice to take all your antibiotics may be wrong

Malaria cases in Florida and Texas: Here’s what you need to know

A new deal aims to ramp up use of AI in rehab care decisions

Hepatitis C has a cure — but many Americans still lack access to it

Test for long Covid? Researchers find new clue in blood samples

hotspot

Eli Lilly, Pfizer, and others want in on the online prescription market

New brain studies show LSD's effects on the brain in full color

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Independent physicians launch a new lobbying group

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

eGenesis tests gene

leisure time

hotspot

hotspot

focus